- Home
- SJT vs ABEO Comparison
SJT vs ABEO Comparison
Compare SJT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | ABEO |
|---|---|---|
| Founded | 1980 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.8M | 281.0M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | SJT | ABEO |
|---|---|---|
| Price | $6.10 | $5.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 199.4K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | $24,557.00 | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $4.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.77 | $3.93 |
| 52 Week High | $7.22 | $7.54 |
Technical Indicators
Market Signals| Indicator | SJT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 49.49 |
| Support Level | $5.74 | $5.05 |
| Resistance Level | $6.09 | $5.41 |
| Average True Range (ATR) | 0.24 | 0.23 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 82.05 | 28.61 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.